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Abstract
Background: In the pathophysiology of hyponatraemia in malaria, the relative contribution of appropriate and
inappropriate arginine vasopressin (AVP) release is unknown; the trigger for inappropriate AVP release is also
unknown.
Methods: Serum copeptin, a stable and sensitive marker for AVP release, was analysed in a large cohort of patients
with imported malaria (204 patients) and in a small prospective substudy (23 patients) in which urine sodium and
osmolality were also available. Hyponatraemia was classified as mild (serum sodium 131-134 mmol/l) and
moderate-to-severe (< 131 mmol/l).
Results: Serum copeptin on admission was higher in patients with moderate-to-severe hyponatraemia (median
18.5 pmol/L) compared with normonatraemic patients (12.7 pmol/L, p < 0.05). Despite prompt fluid resuscitation,
the time to normalization of serum sodium was longer in patients with moderate-to-severe hyponatraemia
(median 2.9 days) than in patients with mild hyponatraemia (median 1.7 days, p < 0.001). A poor correlation was
found between serum sodium and copeptin levels on admission (rs = -0.17, p = 0.017). Stronger correlations were
identified between serum C-reactive protein and copeptin (rs = -0.36, p < 0.0001) and between serum C-reactive
protein and sodium (rs = 0.33, p < 0.0001). Data from the sub-study suggested inappropriate AVP release in seven
of 13 hyponatraemic malaria patients; these patients had significantly higher body temperatures on admission.
Conclusions: In hyponatraemic patients with imported malaria, AVP release was uniformly increased and was
either appropriate or inappropriate. Although the exact trigger for inappropriate AVP release remains unknown, the
higher body temperatures, correlations with C-reactive protein and long normalization times of serum sodium,
suggest an important role of the host inflammatory response to the invading malaria parasite.
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Background
Hyponatraemia is a common finding in imported malaria
and associated with severe Plasmodium falciparum
malaria [1]. Nevertheless, its pathophysiology remains
incompletely understood. Hyponatraemia is primarily a
water balance disorder and usually caused by increased
secretion of arginine vasopressin (AVP). With regard to
hyponatraemia in malaria, some studies found evidence
for “appropriate” vasopressin release due to hypovolaemia
[2] whereas other studies found evidence for “inappropri-
ate” vasopressin release [3,4]. There is, however, no con-
sensus regarding the relative contributions of these
mechanisms in the pathophysiology of hyponatraemia in
malaria.
AVP is a key hormone in maintaining fluid balance
and vascular tone [5]. Despite these important physiolo-
gical functions, measurement of mature AVP is difficult
and subject to preanalytical and analytical errors [6].
Recently, copeptin, a 39-amino acid glycopeptide that
comprises the C-terminal moiety of the AVP precursor
(CT-proAVP) was demonstrated to be a stable and sen-
sitive marker for AVP release [6-9]. Furthermore, a
number of studies have now shown that measurement
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of serum copeptin or calculation of the serum copeptin
to urine sodium ratio is useful in the differential diagno-
sis of fluid and electrolyte disorders [10,11]. In the pre-
sent study, serum copeptin levels were evaluated in a
large cohort of patients with imported malaria to further
explore the role of AVP in the pathophysiology of hypo-
natraemia in malaria.
Methods
Patients
The Harbour Hospital is a 161-bed general hospital
located in Rotterdam, The Netherlands. It also harbours
the Institute for Tropical Diseases, which serves as a
national referral centre. The Rotterdam Malaria Cohort
consists of all patients diagnosed with malaria at the Insti-
tute for Tropical Diseases in Rotterdam. In the period
1999-2010 the Rotterdam Malaria Cohort comprised 519
cases of imported malaria. Of all patients, anonymized
demographic, clinical and laboratory data are routinely
collected and stored in an electronic database. Moreover,
in a large number of patients serum samples taken on
admission were stored. For the present study, anonymized
data from patients who entered the Rotterdam Malaria
Cohort between January 1999 and December 2010 were
used to estimate the prevalence of hyponatraemia in
imported malaria at time of first presentation as well as
for the follow-up of sodium levels after treatment during
admission. For those patients with stored serum samples,
copeptin levels were measured retrospectively. In a small
sub-study serum copeptin levels were measured prospec-
tively in addition to urinary sodium and osmolality.
Laboratory investigations
All available laboratory data were measured on admission
with the use of routine procedures. In contrast, copeptin
levels were retrospectively measured in stored serum sam-
ples with a commercial sandwich immunoluminometric
assay (Brahms Copeptin, Thermo Fisher Scientific, Hen-
nigsdorf/Berlin, Germany) as described [9]. Normal values
for serum copeptin in healthy volunteers range between
1.70 and 11.25 pmol/L [9]. Blood smears (thin and thick
films) were obtained from finger pricks and stained with
Giemsa for parasite counts. Malaria was diagnosed by
Quantitative Buffy Coat analysis, P. falciparum Histidine-
Rich-Protein 2 screening (now ICT Malaria, Binax) and
conventional microscopy with subsequent specification of
the Plasmodium species.
Definitions
Severe malaria
Patients were considered as having severe P. falciparum
malaria if they met the recently updated World Health
Organization (WHO) criteria for severe malaria on
admission or during hospitalization [12]. These criteria
differ from the preset criteria [13] that were used to
define severe malaria in previous studies [1].
Coma acidosis malaria (CAM) score
Of each patient with severe disease an admission CAM
score, a 5-point (0-4 points) score calculated as the sum
of the base deficit score (0-2 points) and Glasgow Coma
score (0-2 points), was given [14].
Hyponatraemia
Hyponatraemia was defined as a serum sodium concen-
tration of less than 135 mmol/L. Mild hyponatraemia
was defined as a serum sodium concentration 131-134
mmol/L, whereas moderate hyponatraemia was defined
as a serum sodium concentration 125-130 mmol/L. The
threshold of < 131 mmol/Lwas chosen because a previous
study found that a sodium level below 131 mmol/L was
an independent predictor for severe disease in imported
malaria [1]. Severe hyponatraemia was defined as a
serum sodium level below 125 mmol/L. Given the low
number of samples of patients with severe hyponatraemia
in the copeptin study, these patients were grouped with
the patients with moderate hyponatraemia to form the
moderate-to-severe hyponatraemia group.
Inappropriate vs appropriate AVP secretion
A recent study found that the serum copeptin to urine
sodium ratio may be used to differentiate normovolaemic
hyponatraemia (ratio ≤ 30 pmol/mmol) from hypovolae-
mic hyponatraemia (ratio > 30 pmol/mmol) [10]. The
most common example of normovolaemic hyponatraemia
is the syndrome of inappropriate antidiuresis [15] and,
therefore, a ratio ≤ 30 pmol/mmol was used to define
inappropriate AVP release. Conversely, AVP release dur-
ing hypovolaemic hyponatraemia is considered “appropri-
ate” and, therefore, appropriate AVP release was defined
as a ratio > 30 pmol/mmol.
Statistical analysis
All data are reported as medians (range). Univariate com-
parisons were performed using the Kruskall-Wallis test
(three groups) with Dunn’s post-hoc tests, or the Mann-
Whitney test (two groups) for not normally distributed
data. Normally distributed data were compared with
unpaired t-tests or unpaired t-tests with Welch correction,
as appropriate. Correlations were analysed using Spearman
rho (rs) and Wilcoxon’s signed rank test. Kaplan-Meier
survival curves for resolution of hyponatraemia after treat-
ment were analysed with the Mantel-Cox log-rank test.
Results
Prevalence of hyponatraemia in imported malaria and its
distribution among the various plasmodium species
Of the 519 cases in the Rotterdam Malaria Cohort
1999-2010, 10 (1.9%) patients had a severe hyponatrae-
mia on admission, 60 (11.6%) patients had moderate
hyponatraemia, whereas 166 (32.0%) malaria patients
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had mild hyponatraemia on admission, respectively. In
the remaining 283 (54.5%) patients the sodium level on
admission was normal. Of the 54 P. falciparum malaria
patients fulfilling the criteria for severe disease, 5 (9.3%)
patients had a severe hyponatraemia on admission, 20
(37.0%) patients had moderate hyponatraemia, whereas
hyponatraemia was mild in 18 (33.3%) patients with
severe malaria. Eleven (20.4%) patients with severe
malaria had a normal sodium on admission, including
the two patients who died. Of the 312 patients with
uncomplicated P. falciparum malaria, severe hypona-
traemia was present on admission in 4 (1.3%) patients,
moderate hyponatraemia in 33 (10.6%) patients and a
mild hyponatraemia was found in 105 (33.7%) patients
on admission, respectively. Serum sodium concentra-
tions were normal in the remaining 170 (54.5%) patients
with uncomplicated P. falciparum malaria. Of the 153
patients with non-P. falciparum malaria, severe hypona-
traemia was present in 1 (0.7%) patient, moderate hypo-
natraemia in 7 (4.6%) patients, mild hyponatraemia in 43
(28.1%) patients, and 102 (66.7%) patients had normal
serum sodium concentrations on admission, respectively.
Characteristics of the patients with severe malaria
When focusing on the 54 patients with severe malaria in
the Rotterdam Malaria Cohort, these patients presented
with the following severity criteria: hypotension (n = 1);
impaired consciousness (n = 8) or unrousable coma char-
acterized by a GCS ≤9 (n = 3); severe anaemia character-
ized by a haemoglobin level ≤3.0 mmol/L (n = 2) or a
packed cell volume < 0.20 (n = 6); blackwater fever (n =
1); renal impairment characterized by a creatinine level ≥
265 μmol/L (n = 6); liver impairment characterized by a
total bilirubin level ≥ 50 mmol/L (n = 29); hyperlactatae-
mia characterized by a lactate ≥ 5 mmol/L (n = 6); hyper-
parasitaemia characterized by a parasite load ≥ 5% (n = 34;
on admission to the intensive care unit n = 40) and schi-
zontaemia (n = 27), respectively. Of 30 patients with
severe malaria a CAM score could be calculated on admis-
sion. The median CAM score was 1, and the scores ranged
from 0 to 3. Nine patients had a CAM score of 0, 16
patients a CAM score of 1, four patients had a CAM score
of 2, whereas 1 patient had a CAM score of 3.
Thirty-six patients received intravenous treatment with
quinine, 11 patients were treated with intravenous artesu-
nate. Four patients were solely treated with oral anti-
malarials and the treatment mode was unknown in three
patients. Thirty-two patients received exchange transfu-
sion. Details of this adjunct therapy for severe malaria are
published elsewhere [16]. Sixteen of 54 patients were
referred from surrounding hospitals. There were no statis-
tically significant differences between blood glucose levels
(glucose 6.3 ± 1.7 mmol/L vs 7.8 ± 5.0 mmol/L, p =
0.1099) and serum sodium levels on admission (sodium
133 ± 7 mmol/L vs 130 ± 4 mmol/L, p = 02491) between
patients referred from other hospital (n = 16) and those
patients directly referred to the Institute for Tropical Dis-
eases (n = 38), making a significant contribution of dex-
trose or glucose infusion on serum sodium levels on
admission unlikely in the referred patients.
Follow-up of hyponatraemia during hospitalization
In a subset of 151 malaria patients with hyponatraemia
from the Rotterdam Malaria Cohort, serum sodium levels
were measured consecutively during hospitalization. Fifty-
eight patients had moderate-to-severe hyponatraemia (16
with severe P. falciparum malaria; 38 patients with
uncomplicated P. falciparum malaria; four non-falciparum
malaria) and hyponatraemia was mild in 93 patients (11
patients with severe P. falciparum malaria; 76 with
uncomplicated P. falciparum infection and six non-falci-
parum infections). As shown in Figure 1, time to normali-
zation of serum sodium was significantly longer in
patients with moderate-to-severe hyponatraemia (median
time to normalization of sodium 2.9 days) than in patients
with mild hyponatraemia on admission (median time to
normalization of sodium 1.7 days, p < 0.001). In approxi-
mately 20% of the malaria patients with moderate-to-
severe hyponatraemia, serum sodium levels did not nor-
malize after one week of antimalarial treatment and infu-
sion of isotonic saline.
Evaluation of the role of copeptin in the pathophysiology
of hyponatraemia in imported malaria
In 204 malaria patients from the Rotterdam Malaria
Cohort copeptin was measured in stored serum samples
Figure 1 Kaplan-Meier survival curve of restoration of
hyponatraemia throughout hospitalization for malaria. Separate
curves for patients with mild and moderate-to-severe (labelled as
“severe”) hyponatraemia on admission are given. Mantel-Cox log-rank
test showed a significant difference between the two curves (p = 0.002).
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and related to previously established laboratory para-
meters on admission. The general characteristics of the
patients participating in the copeptin study are shown in
Table 1. In general, patients with moderate-to-severe
hyponatraemia presented more ill, as illustrated by their
higher body temperatures, pulse rates, CRP and creati-
nine levels. Elevated creatinine levels were frequently
observed: in 12 of 31 (38.7%) patients with moderate-to-
severe hyponatraemia, in 10 of 68 (14.7%) patients with
mild hyponatraemia and in 20 of 105 (19.0%) of normo-
natraemic patients, respectively. Only two patients with
severe P. falciparum malaria had a creatinine level
exceeding the WHO threshold of 265 μmol/L for renal
impairment [12]. These patients both presented with
moderate-to-severe hyponatraemia on admission. Serum
copeptin levels on admission were significantly higher in
patients with moderate-to-severe hyponatraemia (med-
ian 18.5 pmol/L) as compared with normonatraemic
patients (12.7 pmol/L) but not with malaria patients
who presented with mild hyponatraemia (13.2 pmol/L,
Figure 2). Copeptin levels exceeding the 97.5 percentile
of normal healthy individuals (corresponding to a
copeptin level of 11.25 pmol/L) were significantly (p =
0.0099, Chi square test for trend) more often observed
in malaria patients presenting with moderate-to-severe
hyponatraemia (25 of 31 [81%] patients) than in patients
with patients with mild hyponatraemia (47 of 68 [69%]
patients) and normonatraemia (60 of 105 [57%]
patients). A poor correlation was found between serum
sodium and copeptin levels on admission (Figure 3, rs =
-0.17, p = 0.017). In contrast, stronger correlations were
demonstrated between CRP and copeptin (Additional
file 1 rs = -0.36, p < 0.0001) on the one hand and
between CRP and sodium (Additional file 2 rs = 0.33,
p < 0.0001) on the other hand.
Urine biochemistry
In a subset of 23 malaria patients urine sodium and urine
osmolality were measured in parallel with measurement
of serum copeptin. The main outcome measures are
shown in Table 2. In none of the 13 hyponatraemic
patients, serum glucose exceeded 10 mmol/L, excluding
hyperglycaemia as a significant cause of hyponatraemia.
When the 13 hyponatraemic malaria patients were cate-
gorized according to the serum copeptin to urine sodium
ratio, 7 hyponatraemic patients fulfilled the criteria for
inappropriate AVP secretion. Median copeptin levels in
patients with appropriate AVP release were twofold
higher than in patients with inappropriate AVP release
(23.5 vs 11.4 pmol/L, Table 2). There were no significant
differences in creatinine, haematocrit or urea to creati-
nine ratio between hyponatraemic malaria patients with
Table 1 Characteristics of 204 malaria patients in the copeptin study.
Moderate-to-severe hyponatraemia
(n = 31)
Mild hyponatraemia
(n = 68)
Normonatraemia
(n = 105)
P-value*
Demographics
Age, years 42 (11-64) 40 (13-69) 39 (8 - 70) n.s.
Male, female, n (%) 22 (71), 9 (29) 52 (76), 16 (24) 77 (73), 28 (27) n.s.
Malaria species
falciparum, non-falciparum, n (%) 26 (84), 5 (16) 54 (79), 12 (21) 61 (58), 44 (42) 0.0008
Severe malaria, n (%) 10 (40) 10 (40) 5 (20) < 0.0001
Parasite load#, parasites/μL 85900 (400 - 567000) B < 0,001 11032 (2 - 860000) 4600 (30 - 1380600) 0.0013
Vital signs on admission
Body temperature, °C 39.0 (35.7 - 40.8) 38.9 (35.7 - 41.2) 38.2 (36.0 - 41.2) 0.0315
Pulse rate, beats per minute 100 (58 - 140 ) B < 0,01 95 (64 - 130) 85 (60 - 130) 0.0109
Systolic blood pressure, mm Hg 120 (80 - 147) 120 (88 - 165) 120 (95 - 196) n.s.
Laboratory data on admission
C-reactive protein, mg/L 159 (32 - 352) A < 0,01; B < 0,001 101 (7 - 310) C < 0,05 78 (7 - 407) < 0.0001
Haematocrit, L/L 0.35 (0.15 - 0.50) A < 0,01 0.41 (0.12 - 0.52) 0.39 (0.26 - 0.53) 0.0006
Serum glucose, mmol/L 6.9 (4.1 - 26.0) B < 0,05 7.0 (4.2 - 10.3) C < 0,001 6.3 (4.1 - 14.9) 0.0003
Serum creatinine, μmol/L 111 (70 - 1081) B < 0,05 97 (55 - 135) 93 (46 - 208) 0.0180
Serum urea, mmol/L 6.4 (3.6 - 55.8) B < 0,01 5.2 (2.2 - 13.5) 4.9 (2.7 - 21.1) 0.0061
Prerenal azotaemia&, n (%) 2 (6) 2 (3) 2 (2) n.s.
Copeptin, pmol/L 18.5 (3.3 - 91.5) B < 0,05 13.2 (1.6 - 71.2) 12.7 (1.6 - 82.9) 0.0268
Duration hospitalisation, days 6 (1 - 13) B < 0,001 5 (0 - 11) C < 0,001 3 (0 - 12) < 0.0001
Parameters at initial presentation are shown in relation to serum sodium level on admission. Data are given as median (range) or as indicated otherwise.
* Univariate comparison were performed using Kruskall-Wallis (P-values are given in the column) and Dunn’s post-hoc tests (p-values in superscript). A:
comparison of severe hyponatraemia vs mild hyponatraemia; B: comparison of severe hyponatraemia vs normonatraemia; C: comparison of mild hyponatraemia
vs normonatraemia. # P.falciparum parasite load only. &defined as ratio serum urea/serum creatinin > 1:10; n.s. = denotes “not significant difference”
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inappropriate or appropriate AVP secretion, even though
four patients with appropriate AVP secretion had a crea-
tinine level above the normal range (two of them fulfilled
the WHO criterion for renal impairment). All patients
with inappropriate AVP secretion had creatinine levels
within the normal range. Urine osmolality values were
significantly higher in patients with inappropriate AVP
release (median 780 mOsm/kg) than in patients with
appropriate AVP release (480 mOsm/kg) or normona-
traemic patients (484 mOsm/kg). Patients with inap-
propriate AVP release also had significantly higher body
temperatures on admission than hyponatraemic patients
with appropriate AVP release.
Discussion
Copeptin, the C-terminal glycopeptide domain of pro-
vasopressin, is co-secreted with AVP from the posterior
pituitary in hyperosmolar states and upon multiple non-
osmotic stimuli, such as hypotension, pain, and other
non-specific causes of stress [6,8]. Circulating copeptin
levels are therefore thought to reflect the activity of the
neuroendocrine stress axis. To gain more insight in the
pathophysiology of hyponatraemia in malaria and in par-
ticular the role of AVP, serum copeptin was measured in
a large cohort of 204 patients with imported malaria. In
malaria patients the median serum copeptin levels were
three to five-fold higher than the median level of 4.2
pmol/L observed in 359 healthy volunteers [8]. In fact,
the proportion of malaria patients with copeptin levels
above the 97.5th percentile of normal significantly
increased with decreasing sodium levels (Figure 3). More-
over, in absolute terms, patients with moderate-to-severe
hyponatraemia also had significantly higher copeptin
levels than normonatraemic malaria patients on admis-
sion (Figure 2). Because the physiological stimulus for
AVP release is hypertonicity, elevated AVP or copeptin
levels in the context of hyponatraemia indicate a patholo-
gical setting. That is, during normal physiology, the
development of hyponatraemia ought to suppress AVP
release and to result in a maximally dilute urine with a
low urine osmolality [5,17].
A recent study found that the ratio of serum copeptin
to urine sodium may be used to differentiate inappropri-
ate from appropriate AVP secretion [10]. To further
investigate the antidiuretic effect of AVP at the level of
the target organ, urine sodium and osmolality were pro-
spectively studied in parallel with measurements of
serum copeptin levels in a subset of 13 hyponatraemic
and 10 normonatraemic malaria patients on admission.
Based on the serum copeptin to urine sodium ratio, six
patients had appropriate AVP release, while AVP release
was inappropriate in seven patients. Hyponatraemic
patients with inappropriate AVP release had significantly
higher urine osmolality values than observed in patients
with an appropriate AVP response or in normonatraemic
patients. This suggests active water reabsorption by the
kidneys in malaria patients with inappropriate AVP
release. Why inappropriate AVP release results in a
higher urine osmolality than appropriate AVP release is
unclear. One could speculate that in the group with
Figure 2 Box- and whiskerplot of copeptin levels in malaria
patients with a normal serum sodium concentration on
admission (n = 105) and in patients with mild hyponatraemia
(n = 68) and moderate-to-severe (labelled as “severe”)
hyponatraemia (n = 31) on admission. The box indicates the
lower and upper quartiles and the central line represents the
median; the end of the whiskers reflect the 2.5th en 97.5th
percentile of copeptin in malaria patients.
Figure 3 Dot plot of relationship between serum copeptin and
serum sodium. A weak but significant inverse relationship was
observed (rs = -0.17, p = 0.017).
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appropriate AVP release, the renin angiotensin system
was likely also activated, leading to increased renal
sodium reabsorption. Because urine sodium is a major
determinant of urine osmolality, a lower urine sodium
would, therefore, result in a lower urine osmolality in
malaria patients with appropriate AVP release.
From a pathophysiological point of view there may be
two possible explanations for the increased serum copep-
tin levels despite the presence of hypotonicity. First,
volume regulation may have overruled osmoregulation if
there was true hypovolaemia [18] or a low effective arterial
blood volume [19]. This mechanism is mediated via baror-
eceptors in the vasculature and is often referred to as
“appropriate” AVP release. In 6 of 13 hyponatraemic
patients with available urine biochemistry data AVP
release was considered appropriate based on the serum
copeptin to urine sodium ratio. However, in a substantial
number of patients with moderate-to-severe hyponatrae-
mia, the hyponatraemia persisted for more than 7 days
despite infusion of isotonic saline, rendering persistence of
hypovolaemia an unlikely explanation (Figure 1). Hence,
other mechanisms must apply in a substantial number of
malaria patients with hyponatraemia.
The second explanation for elevated copeptin levels
despite the presence of hypotonicity may involve activation
of central osmoreceptors leading to vasopressin release and
subsequent development of hyponatraemia. This alterna-
tive mechanism could have been mediated through cyto-
kines [20] and resembles the syndrome of inappropriate
antidiuresis, a common cause of hyponatraemia [15]. In
fact, in seven of 13 hyponatraemic malaria patients an
inappropriate release of AVP appeared to be present. Of
potential relevance, in this regard, is the observation that
the pro-inflammatory cytokine interleukin-6 is elevated in
malaria and also implicated in the non-osmotic release of
AVP [21,22]. The delayed normalization of serum sodium
concentration, as was observed in the present study, might
be the consequence of the persistent elevation of pro-
inflammatory cytokines, as has been shown for patients
with severe malaria [23]. Previously, a relationship between
a rise in CRP and the development of in-hospital hypona-
traemia was demonstrated [24]. This is not only another
illustration of a presumed cytokine-driven non-osmotic
release of AVP [20] but also in line with the observed
inverse relationship between serum sodium and CRP levels
on the one hand and CRP and copeptin levels on the other
hand (Additional files 1 and 2). Although several drugs,
such as opiates, non-steroidal anti-inflammatory drugs, and
diuretics, can contribute to hyponatraemia, these drugs
were rarely used in this cohort, and it is common policy
not to administer these drugs to malaria patients because
of their potentially adverse effects. Although thyroid and
adrenal function were not formally assessed, which is
recommended before diagnosing inappropriate AVP
release, the response of hyponatraemia to malaria treat-
ment was highly suggestive of a causal relationship.
The distinction between appropriate and inappropriate
AVP release in hyponatraemic malaria patients may be
relevant with regard to selecting the optimal intravenous
fluid regimen. Because previous studies did not separate
Table 2 Results of parallel measurements of urine and blood samples from hyponatraemic and normonatraemic
malaria patients on admission.
Parameter Hyponatraemic patients
(n = 13)
Normonatraemic patients
(n = 10)
Inappropriate AVP secretion@
(n = 7)
Appropriate AVP secretion
(n = 6)
P-value# P-value*
Vital signs on admission
Body temperature, °C 38.9 (37.6-41.1) 37.4 (35.7-38.6) P = 0.0153 38.3 (36.0-40.1) n.s.
Pulse rate, beats per minute 96 (72-121) 105 (91-120) n.s. 93 (72-125) n.s.
Laboratory data on admission
C-reactive protein, mg/L 158 (60-176) 236 (71-352) n.s. 95 (18-407) n.s.
Haematocrit, L/L 0.39 (0.15-0.44) 0.40 (0.19-0.50) n.s. 0.46 (0.36-0.51) n.s.
Serum Urea:creatinine ratio 0.06 (0.04-0.11) 0.07 (0.05-0.14) n.s. 0.06 (0.03-0.09) n.s.
Serum copeptin, pmol/L 11.4 (7.2 -21.4 ) 23.5 (6.8 -91.5 ) n.a. 12.2 (3.8-49.7) n.a.
Serum copeptin > P97.5, n (%) 4 (57) 5 (83) n.s. 6 (60) n.s
Serum sodium, mmol/L 132 (131-134) 128 (124-132) P = 0.012 138 (135-141) n.a.
Urine osmol, mosmol/kg 780 (540-924) 480 (298-532) P = 0.0022 484 (234-906) P = 0.047
Urine sodium, mmol/L 49 (38-154) 9 (9-47) n.a. 32 (9-164) n.a.
Data are given as median (range) or as indicated otherwise.
Legend to the table: @ = inappropriate AVP secretion was defined as a serum copeptin to urine sodium ratio of ≤ 30 pmol/mmol. #P-values of comparison of
hyponatraemic patients with inappropriate vs appropriate AVP secretion. *P-values of univariate analysis using Kruskall Wallis followed by Dunn’s post hoc tests;
n.s. = not significant difference; n.a. = not applicable (defining criterion).
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hyponatraemic malaria patients on the basis of appropri-
ate or inappropriate AVP secretion, future studies are
necessary to give clinical guidance. In general, however,
hypovolaemia causes appropriate AVP release and
should therefore be treated with isotonic fluids. A
caveat, however, is that serum sodium may rise too
rapidly during treatment of hypovolaemic hyponatrae-
mia with isotonic fluids [25]. The risk of exceeding
recommended correction rates is osmotic demyelination,
although few cases in malaria patients have been
reported. Conversely, during inappropriate AVP release,
the emphasis of therapy should perhaps be more on
aggressive anti-malaria treatment, given the association
with a stronger pro-inflammatory cytokine response. In
this setting, a restrictive intravenous fluid regimen may
prove beneficial, because even isotonic saline can worsen
hyponatraemia during the syndrome of inappropriate
antidiuresis [26]. In this regard, a recent study advocat-
ing restrictive IV-fluid therapy in children with malaria
is also of interest, although no serum sodium values
were reported [27].
A potential limitation of our study is that it remains
debatable whether urine sodium can be considered a
reliable parameter for the establishment of hypovolaemia
in malaria, since circulating cytokines have also been
incriminated in causing tubular injury and therefore
natriuresis [28]. The evidence for the pathogenetic role
of AVP in the pathophysiology of hyponatraemia in
malaria is substantial. The results of the small urine
substudy suggest that appropriate [2,19] and inappropri-
ate [3,29] AVP secretion may both occur in the patho-
physiology of hyponatraemia in imported malaria.
However, the high proportion of patients with appropri-
ate AVP release who had elevated creatinine levels on
admission, combined with the higher pulse rate, haema-
tocrit, serum urea to creatinine ratio and the twofold
increase in median AVP release as compared with
patients with inappropriate AVP secretion, are all in
support of a hypovolaemia-driven release of AVP.
Although speculative, the significantly higher body tem-
peratures observed in patients with inappropriate AVP
release on admission suggests that - at least in part -
the extent of the host inflammatory response to the
invading malaria parasite may play a pivotal role in the
aetiology of cytokine-driven non-osmotic release of
AVP.
Additional material
Additional file 1: Dot plot of relationship between serum C-reactive
protein and serum Copeptin on admission as a function of sodium
level on admission. A significant correlation between C-reactive protein
and serum Copeptin was present (rS = 0.33, p < 0.0001). Patients with
moderate or severe hyponatraemia were grouped (labelled as “severe”).
Additional file 2: Dot plot of relationship between serum C-reactive
protein and serum sodium on admission as a function of copeptin
on admission. Copeptin levels above and below the 97.5th percentile of
normal are separately given. A significant inverse correlation was present
between C-reactive protein and sodium on admission (rS = -0.36, p <
0.0001).
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